A phase II, open-label, randomized, genome-wide association study to evaluate the efficacy of GS-9256 to characterize serum bilirubin elevations in patients with Hepatitis C virus infections

Trial Profile

A phase II, open-label, randomized, genome-wide association study to evaluate the efficacy of GS-9256 to characterize serum bilirubin elevations in patients with Hepatitis C virus infections

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2015

At a glance

  • Drugs GS 9256 (Primary) ; Peginterferon alfa-2a; Ribavirin; Tegobuvir
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 14 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top